Increasing Prevalence Of Autoimmune Diseases Driving Growth: Key Driver Transforming The Leukapheresis Market In 2025

June 19, 2025 11:55 AM IST | By EIN Presswire
 Increasing Prevalence Of Autoimmune Diseases Driving Growth: Key Driver Transforming The Leukapheresis Market In 2025
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, June 19, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034

The leukapheresis market size has grown strongly in recent years, expanding from $66.80 billion in 2024 to $72.23 billion in 2025 at a compound annual growth rate CAGR of 8.1%. The growth in the historic period can mainly be attributed to increasing prevalence of leukemia and autoimmune diseases, rising demand for personalized medicine, growth in stem cell research, improvements in apheresis technologies, expanding clinical trial activities, and greater awareness of immunotherapy applications.

What Is The Projected Future Growth Of The Leukapheresis Market Size?
The market for leukapheresis is expected to see robust growth in the next few years, advancing to reach $97.83 billion in 2029 at a CAGR of 7.9%. This forecasted growth can be attributed to rising demand for personalized cell therapies, an increase in clinical trials in immuno-oncology, growing adoption of regenerative medicine, expansion of biopharmaceutical manufacturing, enhanced reimbursement policies, and amplified awareness of cell-based research and treatment options.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24277&type=smp

What Are The Major Drivers In The Leukapheresis Market Forecast Period?
The forecast period is likely to witness key trends which include improved cell separation technologies, integration of AI for procedure optimization, development of portable leukapheresis devices, advancements in cell and gene therapy, enhanced donor screening methods, and adoption of cloud-based data tracking systems.

The global push to combat the rise of autoimmune diseases is expected to be a primary driver in the ongoing expansion of the leukapheresis market. Autoimmune diseases are conditions where the immune system erroneously attacks the body’s own healthy tissues. Reduced early-life microbial exposure and modern environmental factors have disturbed immune balance, leading to an increase in autoimmune disorders. Leukapheresis can potentially play a vital role in treating these diseases by selectively removing the harmful white blood cells that contribute to the immune system attacking the body's own tissues.

Who Are The Key Industry Players In The Leukapheresis Market?
Major companies operating in the leukapheresis market include Fresenius Kabi, Grifols S.A., Terumo BCT Inc., Nikkiso Co., STEMCELL Technologies Inc., Haemonetics Corporation, Macopharma, Discovery Life Sciences, BioIVT LLC, StemExpress LLC, MEDICA S.p.A, AllCells LLC, Caltag Medsystems Ltd., Miltenyi Biotec, Immune Therapy Holdings AB, Cellsep Laboratories, Accegen Biotec, Key Biologics LLC, HemaCare Corporation, Puriblood Medical, Cytopheron Technologies, and Adacyte Therapeutics.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/leukapheresis-global-market-report

What Are The Emerging Trends In The Leukapheresis Market?
Emerging trends involve these key players focusing on advancements such as developing GMP-grade leukopaks to enhance the quality and efficiency of cell therapy manufacturing. For instance, in November 2024, Sanguine Biosciences, a US-based biotechnology company, launched LeukoCert, a GMP-grade leukopak designed to streamline workflows and accelerate cell therapy development.

How Is The Leukapheresis Market Segmented?
The leukapheresis market is segmented:
1 By Type: Granulocyte Apheresis, Lymphocyte Apheresis, Monocyte Apheresis
2 By Product: Leukapheresis Devices, Centrifugal Devices, Membrane Separators, Leukapheresis Disposables
3 By Application: Research Application, Cancer Research, Immunology Research, Therapeutics Application, Hematologic Disorders, Autoimmune Diseases, Other Applications
4 By End User: Blood Component Providers And Blood Centers, Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Hospitals And Transfusion Centers

Further sub-segments include Granulocyte Apheresis subtypes such as Neutrophil Apheresis, Eosinophil Apheresis, Basophil Apheresis, along with Lymphocyte Apheresis variants like T-Cell Apheresis, B-Cell Apheresis, Natural Killer NK Cell Apheresis and Monocyte Apheresis breakdown into Classical Monocytes, Non-Classical Monocytes, Intermediate Monocytes categories.

Where Is The Growth Centered In Terms Of Regions In The Leukapheresis Market?
North America maintained the largest market share in the leukapheresis market in 2024. However, the fastest growth in the forecast period is expected in the Asia-Pacific region. The leukapheresis market report covers regions which include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, as well as Africa.

Browse Through More Similar Reports By The Business Research Company:
Self-Monitoring Blood Glucose (SMBG) Devices Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/self-monitoring-blood-glucose-smbg-devices-global-market-report

Blood Culture Tests Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/blood-culture-tests-global-market-report

Blood Screening Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.